盐酸替罗非班在外周动脉闭塞性疾病腔内治疗中的应用价值  

Value of Tirofiban Hydrochloride in Intracavitary Therapy of Peripheral Artery Occlusive Disease

作　　者：成军[1] 赵渝[1] 张矛[1] 黄文[1] 

机构地区：[1]重庆医科大学附属第一医院,重庆市400016

出　　处：《中国药房》2011年第26期2469-2470,共2页China Pharmacy

摘　　要：目的:探讨应用替罗非班防治外周动脉介入术后急性血栓形成等并发症的应用价值。方法:回顾性分析67例外周动脉闭塞性疾病患者的临床资料,其中介入配合动脉内注射替罗非班组35例,对照组32例,观察2组治疗效果的差异。结果:替罗非班组无急性支架内血栓及动脉血栓形成,无病例再次手术,无病例死亡;而对照组有8例发生急性支架内血栓及动脉血栓形成,6例再次手术,1例死亡,2组差异显著(P<0.05)。结论:替罗非班可明显减少腔内介入术后并发症的发生,用药安全性较好。OBJECTIVE：To observe the value of tirofiban in the treatment of acute thrombus in peripheral artery intervention surgery. METHODS： Clinical information of 67 patients with peripheral artery occlusive disease was analyzed retrospectively. 35 patients in tirofiban group were given peripheral artery intervention surgery and artery injection of tirofiban, and 32 patients was in control group. The difference of therapeutic efficacy was observed in 2 groups. RESULTS： Acute stent thrombosis and arterial thrombosis did not take place in tirofiban group, no case received operation again, no case died; but in control group, 8 cases developed acute stent thrombosis and arterial thrombosis, 6 cases reoperation, 1 case died. There was significant difference between 2 groups（P〈0.05）. CONCLUSION： Tirofiban can significantly reduce the intervention complications, and it is safe for treatment.

关 键 词：外周动脉闭塞性疾病 介入治疗 替罗非班 

分 类 号：R969.4[医药卫生—药理学] R543.5[医药卫生—药学]